1324027 10632737 3875		
3875		
3875		
Pharmaceutical dosage form comprising a sulfite compound		
Ping Gao		
26648		
Patricia K. Fitzsimmons		
01261/2/US		
20-NOV-2006		
31-JUL-2003		
14:47:56		
Utility		
1 1		

Payment information:

Submitted with Payment	yes
Payment was successfully received in RAM	\$170
RAM confirmation Number	65
Deposit Account	191025

The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:

Charge any Additional Fees required under 37 C.F.R. Section 1.16 and 1.17

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)	Multi Part /.zip	Pages (if appl.)
1	Amendment - After Non-Final Rejection	10632737_resptoOA.pdf	580900	no	9
Warnings:					
Information:					
2	Fee Worksheet (PTO-875)	fee-info.pdf	8301	no	2
Warnings:			·		-
Information:					
		Total Files Size (in bytes):	589201		

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filled and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.